For over a decade, Licener has been trusted across continents as a safe, effective over-the-counter treatment against head lice. But with the EU’s sweeping regulatory reform, the familiar landscape changed dramatically. The new MDR redefined the rules for medical devices — and demanded far more than just proof that a product works.

Licener’s effectiveness and safety had already been well established through clinical trials and years of surveillance on real-world use. Yet the MDR brought a new challenge: (re-)proving every aspect of product design, testing, and monitoring within a unique, European, hyper-integrated framework, often to an almost philosophical degree.

While the additional control and record-keeping load continued to be internationally argued to be excessive, especially for smaller organizations, Pronova saw it as an opportunity: from the ground up, its team designed a lean, modern quality system that not only meets the MDR’s expectations but showcases transparency, control, and continuous improvement.

Even with that solid foundation, the road to CE certification wasn’t exactly a walk in the park. As now learned by many, the MDR might well ask you to prove the sky is blue, and you’d better reference the latest ISO standard on colour measurement while you’re at it.

But perseverance pays off. Every re-test, every review, every audit reinforced the true value of Licener: a plant-based, one-step solution that helps families worldwide deal with head lice safely and effectively, without compromise or comparison.

As the season turns, Licener stands certified and shining — officially the first Class IIa device of its kind registered under the MDR in the European database. It’s a milestone that opens the door to an even brighter future, both within and beyond the EU.

The post Pronova receives CE certification for Licener Head Lice Treatment appeared first on General Investment Fund.

The award was granted for our innovative wart treatment product, Forwarts, which is distinguished by our uniquely developed technology. Forwarts uses a patented valve system that delivers a precisely targeted stream of cooling gas directly onto the wart. This direct spray method is a true step forward in wart cryotherapy, replacing the traditional foam applicator with a faster, more accurate, and more effective treatment.

At the exhibition, we showcased Forwarts to an international audience and proudly celebrated this recognition. Winning this award strengthens Pronova’s position as a leader in innovative self-care solutions and highlights our commitment to setting new standards in healthcare..

CPhI Worldwide is the largest pharmaceutical trade fair in the world, bringing together over 60,000 professionals and 2,500 exhibitors each year. The CPhI Awards shine a spotlight on breakthrough products that redefine quality and effectiveness in the industry. We are honored that Forwarts now stands among them.

For Pronova, this achievement continues a tradition of innovation. Back in 1997, we introduced Wartner, the first successful OTC wart cryotherapy product for home use. With Forwarts, we are once again reshaping the market—making treatments more effective, more accessible, and easier to use. The success of Forwarts suggests that Pronova may once again be on the path to reshaping the OTC market with a new standard in effectiveness and ease of use.

The post Pronova Laboratories wins prestigious CPhI Worldwide Award for most innovative OTC medical device appeared first on General Investment Fund.